Ironwood Total Assets vs Total Liab Analysis
IRWD Stock | USD 3.34 0.18 5.11% |
Ironwood Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ironwood Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ironwood Pharmaceuticals is a good investment. Please check the relationship between Ironwood Pharmaceuticals Total Assets and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
Total Assets vs Total Liab
Total Assets vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ironwood Pharmaceuticals Total Assets account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Ironwood Pharmaceuticals' Total Assets and Total Liab is 0.49. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Liab in the same time period over historical financial statements of Ironwood Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ironwood Pharmaceuticals' Total Assets and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Ironwood Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Assets i.e., Ironwood Pharmaceuticals' Total Assets and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.49 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Assets
Total assets refers to the total amount of Ironwood Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ironwood Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Ironwood Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.4 B, whereas Discontinued Operations is forecasted to decline to (45.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 31.2M | 7.6M | 21.6M | 19.9M | Depreciation And Amortization | 1.5M | 1.4M | 1.6M | 1.5M |
Ironwood Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Short Long Term Debt Total | 431.2M | 453.7M | 475.8M | 415.9M | 715.5M | 751.3M | |
Other Current Liab | 33.4M | 25.3M | 40.6M | 18.3M | 64.3M | 67.6M | |
Total Current Liabilities | 40.9M | 32.7M | 161.7M | 25.5M | 276.1M | 289.9M | |
Total Stockholder Equity | (93.3M) | 62.6M | 605.9M | 652.4M | (346.3M) | (329.0M) | |
Other Liab | 25.0M | 13.3M | 3.5M | 9.8M | 8.8M | 8.3M | |
Property Plant And Equipment Net | 30.2M | 25.5M | 22.9M | 20.3M | 18.2M | 19.6M | |
Current Deferred Revenue | 875K | 28.4M | 39.5M | 1.2M | 1.1M | 1.1M | |
Net Debt | 254.2M | 91.1M | (144.3M) | (240.3M) | 623.4M | 654.6M | |
Retained Earnings | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (1.7B) | (1.6B) | |
Accounts Payable | 5.5M | 661K | 935K | 483K | 7.8M | 7.4M | |
Cash | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Non Current Assets Total | 95.9M | 63.4M | 381.7M | 319.9M | 237.8M | 143.0M | |
Non Currrent Assets Other | 64.9M | 37.1M | 25.5M | 15.9M | 3.6M | 3.4M | |
Other Assets | 64.9M | 54.5M | 358.8M | 299.6M | 1.0 | 0.95 | |
Long Term Debt | 408.0M | 430.3M | 337.3M | 396.3M | 498.3M | 252.1M | |
Cash And Short Term Investments | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Net Receivables | 117.2M | 122.4M | 114.0M | 115.5M | 129.1M | 135.6M | |
Common Stock Total Equity | 154K | 158K | 161K | 162K | 177.1K | 125.3K | |
Common Stock Shares Outstanding | 156.0M | 160.7M | 164.4M | 186.3M | 155.4M | 137.1M | |
Liabilities And Stockholders Equity | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Non Current Liabilities Total | 455.1M | 463.9M | 359.3M | 422.6M | 541.3M | 370.6M | |
Other Current Assets | 11.9M | 10.9M | 11.1M | 9.0M | 12.0M | 17.8M | |
Other Stockholder Equity | 1.5B | 1.5B | 1.5B | 1.3B | 1.4B | 1.0B | |
Total Liab | 496.0M | 496.6M | 521.0M | 448.1M | 817.4M | 454.8M | |
Property Plant And Equipment Gross | 30.2M | 25.5M | 22.9M | 20.3M | 27.1M | 20.1M | |
Total Current Assets | 306.9M | 495.8M | 745.2M | 780.6M | 233.3M | 356.5M | |
Accumulated Other Comprehensive Income | (79K) | (65.2M) | 0.0 | (11.8M) | (3.0M) | (3.2M) | |
Short Term Debt | 1.1M | 6.3M | 120.0M | 6.1M | 202.7M | 212.8M | |
Common Stock | 154K | 158K | 161K | 162K | 156K | 128.1K | |
Property Plant Equipment | 12.4M | 8.9M | 22.9M | 6.3M | 5.7M | 5.4M | |
Net Tangible Assets | (72.0M) | 83.0M | 605.9M | 669.0M | 769.3M | 807.8M | |
Retained Earnings Total Equity | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (626.7M) | (658.1M) | |
Long Term Debt Total | 408.0M | 430.3M | 337.3M | 396.3M | 455.7M | 311.5M | |
Capital Surpluse | 1.5B | 1.5B | 1.5B | 1.3B | 1.6B | 1.3B | |
Capital Lease Obligations | 23.2M | 23.4M | 21.6M | 19.7M | 17.7M | 9.9M | |
Deferred Long Term Liab | 97.6M | 40.1M | 24.3M | 12.1M | 13.9M | 13.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.